Results: Hepatic packing with drainage and blood pressure control were done. Patient received Low Molecular Weight Heparin and Aspirin and improved after 13 days without bleeding.

Conclusions: Spontaneous hepatic rupture is a rare, life-threatening presentation of APS that warrants timely diagnosis and effective control of haemorrhage to prevent maternal and fetal mortality. Early initiation of anticoagulation is both safe and effective in preventing APS complications. Aspirin should be initiated to prevent future thrombosis and pregnancy loss.

Background and aims: To explore utility of Antibodies to Phosphatidylserine/Prothrombin Complex (aPSPT), in Indian Anti phospholipid Syndrome (APS) patients.

Methods: Data of 372 subjects whose sera was tested for aPSPT by ELISA (AESUKU, GERMANY), was retrospectively analysed. Performance of various APLs was compared using non-parametric tests. To ascertain additional utility of aPSPT, patients with suspected APS were categorised into 2 groups i.e. i) those with any one of criteria antibodies positive ii) those with any one APL positivity including anti-PSPT positivity.

Results: In 46 patients of APS, 38 (82.60%) had thrombotic events (21 arterial, 26 venous) and 11 (23.91%) had obstetric events. Lupus anticoagulant was present in 37/46 (80.43%) events (21 arterial, 26 venous) and 11 (23.91%) had obstetric events. SNAPS patients may test positive for aPSPT, thus endorsing its inclusion in classification criteria of APS.

Conclusions: In our study, aPSPT was third most common antibody in APS patients, displaying higher sensitivity and specificity in comparison to IgM anti-β2 GP1 for all APS manifestations except obstetric ones. SNAPS patients may test positive for aPSPT, thus endorsing its inclusion in classification criteria of APS.

Abstract 62 Tabel 2: Comparision of sensitivity and specificity of aPSPT and IgM anti-β2GP1 in definite APS patients

<table>
<thead>
<tr>
<th>Type of Subjects</th>
<th>Number</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>Sensitivity</th>
<th>Specificity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Definite APS (satisfying revised Sapporo criteria)</td>
<td>46</td>
<td>27.3%</td>
<td>38.5%</td>
<td>45.5%</td>
<td>11.5%</td>
</tr>
<tr>
<td>Arterial Events</td>
<td>38.1%</td>
<td>32%</td>
<td>9.5%</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>Venous Events</td>
<td>38.5%</td>
<td>30%</td>
<td>11.5%</td>
<td>25%</td>
<td></td>
</tr>
</tbody>
</table>

Non-criteria manifestations:

50%: 29.4%: 16.7%: 17.6%
Results She showed complete recovery after rituximab.

Conclusions Rituximab can be considered as an effective treatment modality in APLA related chorea where conventional measures have failed.

### ANTIPHOSPHOLIPID SYNDROME LONG TERM FOLLOW UP: REAL LIFE EXPERIENCE OF A SINGLE CENTRE

**Background and aims** The antiphospholipid syndrome (APS) has wide clinical and outcome spectrum overtime. The aim of this study was to assess the real life prevalence of morbimortality APS during 10 year-follow-up of a single referral centre.

**Methods** The cohort included 160 consecutive APS patients followed by the Autoimmune Diseases Unit of Hospital Clinic Barcelona from 2003 to 2013. Epidemiological, clinical, immunological and treatment features were analysed prospectively.

**Results** The cohort consisted of 126 (79%) women and 34 (21%) men. Mean (SD) age at diagnosis was 39 (14) years. The diagnostic causes were thrombosis (56.3%), obstetric morbidity (26.9%) and both (16.9%). 65% were primary APS, 22.5% associated with systemic lupus erythematosus (SLE), 8.8% associated with lupus-like syndrome and 3.7% associated with other diseases. Fifty-five patients were lost to follow-up (3.4% every year). In evolution, 10 primary APS patients were reclassified as SLE-associated APS and 2 patients developed catastrophic APS. Table 1 shows the frequencies of the main APS clinical manifestations at baseline and during the 10-year-follow-up. At diagnosis, 95% received antithrombotic treatment: low dose antiaggregants (39.5%), oral anticoagulants (67.1%), heparin (2.6%). During the study, 72.7% of recurrences were without antithrombotic treatment and 27.3% were despite it. Eleven major bleeding episodes occurred and 2 were fatal. The global mortality rate was 6.9% and 50% in catastrophic APS. Table 2 shows the main causes of death and Figure 1 is a Kaplan–Meier survival curve.

**Conclusions** This study shows long-term morbidity and mortality of a large APS patient cohort and exposed the real-life experience of a referral unit.

---

### ANTIPHOSPHOLIPID SYNDROME – CLINICAL AND IMMUNOLOGICAL CORRELATIONS AND ATHEROSCLEROSIS

**Background and aims** In recent years, it is found that role in atherogenesis plays inflammatory component of immune response. In recent years found unarguably data for accelerated development of atherosclerotic plaques in patients with APS.

Our aim is to investigate the frequency of cardiovascular events and atherosclerosis in patients with primary and secondary antiphospholipid syndrome compared to healthy individuals and patients with systemic lupus erythematosus without antiphospholipid antibodies.

**Methods** We studied 99 patients with APS, 13 SLE and 32 healthy controls. They were tested for aPL antibodies (aCL, anti-b2gpl, anti-prothrombin), ANA-screen, ANA -profile and standart laboratory.

We examine Intima-Media thickness of carotid arteries and Calcium score of: a. coronaria sinister, a. anterior descendens sinister, a. circumflexa sinister, a. coronaria dexter, Aorta, Valvorta and evaluate the atherosclerosis.

**Results** We found strong, statistically significant correlation between aCL antibodies and the presence of plaques in the left common carotid artery (p=0.041) and absent a correlation between aPL titers and presence of carotid plaques. In the group with APS, 33,3% (14) establishes a positive calcium score of coronary arteries, 11.9% (5) positive for aorta, Aortic valve Absent deposits, In the control group positive calcium score is one person (5.8%).

---

**DYSBIOSIS AND GUT BARRIER DYSFUNCTION IN ANTIPHOSPHOLIPID SYNDROME AS REVEALED BY IGA-SEQ PROFILING**

**Background and aims** The antiphospholipid syndrome (APS) is an autoimmune thrombophilic non-gut disorder with high mortality. Various pathogens have been associated with transient antiphospholipid antibody production. We hypothesised that members of the gut microbiota in APS patients could represent a chronic trigger and exhibit heightened adaptive immune responses to the microbiota. The purpose of this study was to explore gut barrier function and faecal IgA-coated microbial composition in APS patients.

**Methods** Stool from 15 APS patients, 5 non-autoimmune thrombotic states, and 12 normal donors (total of 17 controls) was collected. Faecal homogenates were analysed for the gut permeability marker calprotectin and, in parallel, stained with PE-conjugated anti-human IgA prior to cell sort-

**Results** Faecal calprotectin and IgA-coated faecal bacterial levels were significantly higher in APS patients compared to controls (p<0.003; p<0.05). LEfSe analysis of IgA+ fractions showed that the strongest IgA-coated genus is *Blautia* in APS. **Conclusions** These data suggest gut barrier dysfunction and aberrant IgA coating of commensals in APS. Markedly increased IgA coating of *Blautia* in APS might reflect altered gut homeostasis as a *Blautia* species was shown to be part of proinflammatory IgA+ consortium in a recent study in IBD. To our knowledge, this study represents the first 16S rRNA profiling of IgA-coated gut commensals in patients with non-gut autoimmunity.

---

**ANTIPLPHOSPHOLIPID SYNDROME AS REVEALED BY IGA-SEQ PROFILING**

1**WJ Kim*, 2WRuff, 3Aguiar, 4AYu, 3SMVieira, 2SMGarriga, 4MGraven, 3MErkan, 1MAKrieger, 3Cheju Halla General Hospital, Laboratory Medicine, Jeju-si, Republic of Korea; 2Yale School of Medicine, Immunobiology, New Haven, USA; 4Hospital for Special Surgery, Medicine, NewYork, USA; 3Yale School of Medicine, Microbial Pathogenesis, New Haven, USA; 2Yale School of Medicine, Medicine, New Haven, USA

10.1136/lupus-2017-000215.64

**Conclusions** This study shows long-term morbidity and mortality of a large APS patient cohort and exposed the real-life experience of a referral unit.